OMS102
DeviceSubjects will receive implanted OMS102 System.
Other names: abiliti System
NCT Number: NCT01539850
The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Wolfart Klinik, Gräfelfing, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will receive implanted OMS102 System.
Other names: abiliti System
Time frame: 3 months
Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.
Time frame: 3, 6, and 12 months
Percentage of excess body weight loss (%EWL) compared to baseline.
Time frame: 3, 6, and 12 months
Occurrence and severity of all adverse events
Time frame: 3, 6 and 12 months
Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire
Time frame: 3, 6 and 12 months
Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)
Time frame: 3, 6 and 12 months
Any reduction of blood pressure and oral diabetes medications
IntraPace, Inc
Industry
Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07662538
Body Weight, Digestive System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05379088
Behavior, Body Weight
Columbus, Ohio, United States
View Trial DetailsNCT02792166
Body Weight, Glucose Metabolism Disorders
Montreal, Quebec, Canada
View Trial DetailsNCT04197336
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial Details